Croda International Plc (LON:CRDA) Insider Tom Brophy Sells 380 Shares

Croda International Plc (LON:CRDA - Get Free Report) insider Tom Brophy sold 380 shares of the firm's stock in a transaction dated Monday, April 7th. The stock was sold at an average price of GBX 2,643 ($34.59), for a total transaction of £10,043.40 ($13,145.81).

Croda International Stock Performance

LON:CRDA traded up GBX 9 ($0.12) during midday trading on Friday, reaching GBX 2,632 ($34.45). 665,715 shares of the company traded hands, compared to its average volume of 1,762,788. Croda International Plc has a twelve month low of GBX 2,551 ($33.39) and a twelve month high of GBX 5,034 ($65.89). The company has a debt-to-equity ratio of 30.90, a current ratio of 2.72 and a quick ratio of 2.25. The company has a fifty day moving average price of GBX 3,035.46 and a 200 day moving average price of GBX 3,383.86. The firm has a market capitalization of £3.68 billion, a price-to-earnings ratio of 22.62, a price-to-earnings-growth ratio of 1.40 and a beta of 0.74.

Croda International (LON:CRDA - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported GBX 142.60 ($1.87) EPS for the quarter. Croda International had a net margin of 9.98% and a return on equity of 6.96%. On average, analysts expect that Croda International Plc will post 181.8307268 EPS for the current fiscal year.

Croda International Increases Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Thursday, April 10th will be paid a dividend of GBX 63 ($0.82) per share. The ex-dividend date of this dividend is Thursday, April 10th. This represents a yield of 2.03%. This is an increase from Croda International's previous dividend of $47.00. Croda International's payout ratio is presently 93.66%.

Croda International Company Profile

Founded in 1925 with the aim of turning bio-based raw materials into innovative ingredients, Croda International is a speciality chemicals company focused on consumer care and life sciences markets. The company is focused on creating, making and selling innovative ingredients that deliver real benefits to a diverse range of customers and employs more than 6,000 people around the world.